BEND, OR--(Marketwired - Oct 18, 2017) - EVIO, Inc. (OTCQB: EVIO), the nation's leading provider of analytical laboratory cannabis testing, research and advisory services, announces its EVIO Labs division has already exceeded last October's Testing Revenues through the first half of October 2017 with sales surpassing $250,000.
"Our national sales team continues to expand EVIO's service offerings," comments William Waldrop, CEO of EVIO. "After an impressive 2017, in which we exceeded our own internal projections, we are starting the 2018 fiscal year on the right track."
Mr. Waldrop continues, "We are eagerly waiting for the upcoming accreditation of our new pesticide equipment. As mentioned in our 8K, the Oregon Environmental Laboratory Accreditation Program (ORELAP) has provided Monday, October 23, 2017 as their on-site assessment date. As soon our accreditation scope is expanded to include full-service pesticides, the company will be able to perform a majority of our testing in-house. This will tremendously improve our gross margins and overall profitability. Our team has worked tirelessly to ensure we are ready for this fall harvest and the continued growth in both the Oregon and National Markets."
EVIO, Inc. is a life science company that provides accredited analytical testing services and scientific research to the regulated cannabis industry. The Company's EVIO Labs division operating coast-to-coast provides state-mandated ancillary services to ensure the safety and quality of the nation's cannabis supply.
For More Information, visit www.eviolabs.com
Safe Harbor Statement
Any statements in this press release that are not statements of historical fact maybe considered to be forward-looking statements. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at www.sec.gov or www.eviolabs.com